KLOW peptide dosage: what the component studies administered

In plain English

There is no approved or validated human dosage for KLOW peptide. The blend has never been tested in a human study — or any controlled animal study. What does exist is a canonical research-vial composition (80 mg total, split 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV) that independent compounders have converged on, and a body of single-component dose-range data from the preclinical and limited human literature for each of the four peptides.

This page documents that research-context information. None of it is a dosing recommendation. The component doses are not additive into a single 'KLOW dose' — the pharmacokinetic profiles of the four peptides differ too substantially for a single co-formulated vial to maintain all four at matched exposures.

KLOW peptide dosage

The canonical research-vial composition for KLOW is an 80 mg total lyophilized vial, reconstituted with bacteriostatic water for laboratory handling. The split is: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg.

This is not a dose — it is the composition of one research vial as supplied. It reflects a standardized format adopted by independent compounders, not a validated research protocol.

KLOW dosage

No controlled study has tested the KLOW blend at any dose in any species. The 80 mg vial composition is a preparation specification, not a dosing recommendation derived from pharmacological research.

KLOW peptide dosage and frequency

No validated frequency or cycle-length data exists for the blend. Component-level research studies used varying schedules — once daily intraperitoneal injection in rodent tendon models for BPC-157, topical or intraperitoneal administration in the thymosin β4 wound model — and those schedules were designed around single-compound pharmacokinetics, not a co-formulation.

Because the four peptides have markedly different reported half-lives, a frequency that is appropriate for one component's kinetics will not be appropriate for all four simultaneously.

BPC-157 dose context from the research literature

In rodent tendon-repair studies, BPC-157 was administered at 10 μg, 10 ng or 10 pg per rat (intraperitoneal, once daily) in the Staresinic 2003 Achilles transection study ^[2]. The Krivic 2006 Achilles detachment study and the Cerovecki 2010 ligament study did not report specific dose values ^[9][10].

Pharmacokintically, BPC-157 shows a very short elimination half-life (under 30 minutes in the formal 2022 PK study), intramuscular bioavailability of approximately 14–19% in rats and 45–51% in beagle dogs, and excretion via urine and bile ^[8]. The peptide breaks down into small fragments entering normal amino-acid metabolism.

In the 2025 human IV safety pilot (n=2), BPC-157 was administered at 10 mg on day 1 and 20 mg on day 2, each in 250 cc saline as a 1-hour infusion ^[6]. That is a single-session safety observation, not a dosing protocol.

A 2025 narrative review concluded that the dose-response literature remains almost entirely preclinical and that rigorous, large-scale human trials are lacking ^[13]. KLOW research note: BPC-157 contributes 10 mg to the canonical 80 mg vial — the same order of magnitude as the 2025 human pilot, though the route and vehicle differ.

TB-500 dose context from the research literature

Foundational efficacy data for the TB-500 arm derive from thymosin β4 (the full-length native protein, not the Ac-LKKTETQ fragment) studies. In the Malinda 1999 wound model, thymosin β4 was administered topically and intraperitoneally; as little as 10 pg stimulated keratinocyte migration 2–3-fold in migration assays ^[1].

The TB-500 fragment (Ac-LKKTETQ) has not undergone formal human pharmacokinetic characterization. It is distinct from full-length thymosin beta-4, and the dose ranges established for the native protein do not automatically transfer to the fragment.

GHK-Cu dose context from the research literature

In cell-culture validation for the gene-expression work, GHK-Cu showed activity at 1–10 nM ^[5]. In clinical topical studies, formulated creams and serums were used at concentrations not individually reported in the public literature; the skin-regeneration review documented clinical improvements at standard topical concentrations ^[4].

GHK-Cu contributes 50 mg to the canonical 80 mg KLOW vial — the mass-dominant component, about 62.5% by mass — with each molecule carrying a chelated copper(II) ion. For injectable research use, the copper load per vial is therefore substantially higher than in topical cosmetic applications.

KPV dose context from the research literature

In the Dalmasso 2008 mechanistic study, KPV was active at 10 nM in cell-culture (human intestinal epithelial cell lines and Jurkat T cells) and was administered at 100 μM in drinking water in the mouse colitis models ^[3]. The PepT1 transporter Km for KPV is approximately 160 μM.

KPV contributes 10 mg to the canonical 80 mg KLOW vial. The route context matters: most KPV research was conducted in oral or cell-culture settings, not in the subcutaneous injectable context implied by research-vial use. The in vivo bioavailability and systemic exposure of injected KPV have not been formally characterized.

Stability and compatibility notes

KLOW is supplied as a lyophilized blend. Reconstituted solution is typically refrigerated for laboratory handling. A theoretical compatibility consideration: copper(II) in GHK-Cu can participate in redox chemistry when co-dissolved with the other three peptides in one vial. This has not been formally characterized for this mixture.

The pharmacokinetic mismatch is inherent and worth stating plainly: BPC-157's elimination half-life under 30 minutes ^[8] means it clears far faster than GHK-Cu's reported activity profile. A single co-formulated dose cannot maintain all four components at matched tissue exposures — a structural limitation that has not been addressed by any published research.